Eli Lilly (LLY)

The top stocks are showing relative strength. Two are defensive growth plays.

There are still great opportunities in an otherwise volatile market.

Eli Lilly holds a dominant market share in the weight loss treatment category.

The pharma titan is expanding into new markets.

Eli Lilly is a leader in the revolutionary GLP weight-loss market. Lilly was one of 28 stocks new to best stock lists Friday.

Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's commit...

The smartphone could be a thing of the past if Snap has its way. But at $2,195, it could be a tall order to sell Specs to consumers, even if they were stylish.

Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.

These aren't for the faint of heart.

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.

Nancy Pelosi Stock Tracker told investors to "keep an eye" on Eli Lilly and Nokia after Trump praised the companies in Pennsylvania.

These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.

What Happened? Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to ...

Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally.

Consistency can do a lot of the heavy lifting for you.

White House denies reports Trump received Eli Lilly's unapproved obesity drug retatrutide through an FDA program.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.

The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.

These healthcare stocks may be the building blocks of a winning portfolio.